AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Journal of Traditional Chinese Medical Sciences Article
PDF (3.1 MB)
Cite
EndNote(RIS) BibTeX
Collect
AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Effects of Qidi Tangshen granules and their separate prescriptions on podocytes in mice with diabetic nephropathy

Borui Yua, Hongfang Liua( ), Xue Gaob, Qingqing Liua, Qing Dua, Xiangming Wanga, Zhichao Ana, Lin Wanga, Huidi Xiea
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100700, China
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 102488, China

Peer review under responsibility of Beijing University of Chinese Medicine.

Show Author Information

Abstract

Objective

Previous studies have found that Qidi Tangshen granules (QDTS), a combination therapy of supplementing essence (Tianjing, TJ) and unblocking the collaterals (Tongluo, TL), can reduce kidney damage in db/db mice. This study aimed to explore the effect of QDTS and their separate prescriptions on podocytes in mice with diabetic nephropathy.

Methods

The db/db mice were used in this experiment as an animal model, while wild-type C57BL/6J mice were used as normal controls. At the age of 12 weeks, the db/db mice were randomly divided into 5 groups (db/db, db/db + valsartan, db/db + QDTS, db/db + TJ and db/db + TL). The urine albumin excretion ratio (UAE) was measured by enzyme-linked immunosorbent assay before and after the intervention. The ultrastructure of the kidney podocytes was observed by transmission electron microscopy. The protein expression levels of nephrin and desmin were detected by immunohistochemistry.

Results

QDTS and their separate prescriptions significantly decreased the UAE and attenuated the renal pathological injury. QDTS and their separate prescriptions also reduced the fusion rate of the foot processes and increased the expression of nephrin protein. In contrast, QDTS and their separate prescriptions (TJ and TL) reduced the expression level of desmin protein.

Conclusion

QDTS and their separate prescriptions might reduce diabetes-induced renal injury by reducing podocyte damage. The therapeutic effect of QDTS was more pronounced than TJ and TL.

Keywords

Diabetic nephropathyPodocytesQidi Tangshen granulesSeparate prescriptionsProteinuriaTraditional Chinese medicine treatmentSupplement essenceUnblock the collaterals

References

1

Roy A, Maiti A, Sinha A, et al. Kidney disease in type 2 diabetes mellitus and benefits of sodium-glucose cotransporter 2 inhibitors: a consensus statement. Diabetes Ther. 2020;11(12):2791-2827.
Crossref Google Scholar
2
International Diabetes Federation. IDF diabetes atlas. https://diabetesatlas.org/en/resources/. Accessed December 23, 2019.
3

Cheng HT, Xu X, Lim PS, Hung KY. Worldwide epidemiology of diabetes-related end-stage renal disease, 2000–2015. Diabetes Care. 2021;44(1):89-97.
Crossref Google Scholar
4

Sagoo MK, Gnudi L. Diabetic nephropathy: an overview. Methods Mol Biol. 2020;2067:3-7.
Crossref Google Scholar
5

Zhang L, Zhao MH, Zuo L, et al. China kidney disease network (CK-NET) 2015 annual data report. Kidney Int Suppl. 2019;9(1):1-81.
Crossref Google Scholar
6

Association AD. Microvascular complications and foot care: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(1):124-138.
Crossref Google Scholar
7

Sulaiman MK. Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management. Diabetol Metab Syndrome. 2019;11:7.
Crossref Google Scholar
8

Chen X, Chen J, Li X, et al. Activation of mTOR mediates hyperglycemia-induced renal glomerular endothelial hyperpermeability via the RhoA/ROCK/pMLC signaling pathway. Diabetol Metab Syndrome. 2021;13(1):105.
Crossref Google Scholar
9

Szrejder M, Piwkowska A. AMPK signalling: implications for podocyte biology in diabetic nephropathy. Biol Cell. 2019;111(5):109-120.
Crossref Google Scholar
10

Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes. 2005;54(6):1626-1634.
Crossref Google Scholar
11

Li JJ, Kwak SJ, Jung DS, et al. Podocyte biology in diabetic nephropathy. Kidney Int Suppl. 2007(106):36-42.
Crossref Google Scholar
12

Wei PZ, Szeto CC. Mitochondrial dysfunction in diabetic kidney disease. Clin Chim Acta. 2019;496:108-116.
Crossref Google Scholar
13

Tung CW, Hsu YC, Shih YH, Chang PJ, Lin CL. Glomerular mesangial cell and podocyte injuries in diabetic nephropathy. Nephrology. 2018;23(4):32-37.
Crossref Google Scholar
14
HuJYLiuHFZhangXWPathogenesis of diabetic nephropathy with essence depletion and collateral impedimentJ Beijing Univ Tradit Chin. Med.2019421811

Hu JY, Liu HF, Zhang XW. Pathogenesis of diabetic nephropathy with essence depletion and collateral impediment. J Beijing Univ Tradit Chin. Med.. 2019;42(1):8-11 [Chinese].
Google Scholar
15

Gao X, Liu H, An Z, He Q. QiDiTangShen granules reduced diabetic kidney injury by regulating the phosphorylation balance of the tyrosine and serine residues of insulin receptor substrate 1. Evid Based Compl Alternat Med. 2018;2018:1-12.
Crossref Google Scholar
16

Wang XM, Zhao L, Ajay AK, et al. Qiditangshen granules activate renal nutrient-sensing associated autophagy in db/db Mice. Front Physiol. 2019;10:1224.
Crossref Google Scholar
17

Park S, Rich J, Hanses F, Lee JC. Defects in innate immunity predispose C57BL/6J-Leprdb/Leprdb mice to infection by staphylococcus aureus. Infect Immun. 2009;77(3):1008-1014.
Crossref Google Scholar
18

King AJ. The use of animal models in diabetes research. Br J Pharmacol. 2012;166(3):877-894.
Crossref Google Scholar
19

Xu BH, Sheng J, You YK, et al. Deletion of smad3 prevents renal fibrosis and inflammation in type 2 diabetic nephropathy. Metabolism. 2020;103:154013.
Crossref Google Scholar
20

Eid S, Sas KM, Abcouwer SF, et al. New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism. Diabetologia. 2019;62(9):1539-1549.
Crossref Google Scholar
21

Microvascular complications group of Chinese diabetes society. Clinical guideline for the prevention and treatment of diabetic kidney disease in China (2021 edition). Chin J Diabetes Mellitus. 2021;13(8):762-784 [Chinese].
Google Scholar
22

Zhou GY, Cheung AK, Liu X, Huang YF. Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation. Clin Sci (Lond). 2014;126(10):707-720.
Crossref Google Scholar
23

Ruggenenti P, Trillini M, P Barlovic D, et al. Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: a prospective, randomized, controlled trial. Diabetes Obes Metabol. 2019;21(5):1177-1190.
Crossref Google Scholar
24
OshimaMNeuenBLLiJWEarly change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a postHoc analysis from the CREDENCE trialJ Am Soc Nephrol2020311229252936

Oshima M, Neuen BL, Li JW, et al. Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a postHoc analysis from the CREDENCE trial. J Am Soc Nephrol. 2020;31(12):2925-2936.

10.1681/ASN.2020050723
Crossref Google Scholar
25

Selby NM, Taal MW. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obes Metabol. 2020;22(1):3-15.
Crossref Google Scholar
26

Kostovska I, Trajkovska KT, Cekovska S, et al. Role of urinary podocalyxin in early diagnosis of diabetic nephropathy. Rom J Intern Med. 2020;58(4):233-241.
Crossref Google Scholar
27
AltintasMMReiserJMore expression, less function: cleaved dynamin in glomerular kidney diseaseJ Pathol20192474413415

Altintas MM, Reiser J. More expression, less function: cleaved dynamin in glomerular kidney disease. J Pathol. 2019;247(4):413-415.

10.1002/path.5217
Crossref Google Scholar
28

Somlo S, Mundel P. Getting a foothold in nephrotic syndrome. Nat Enet. 2000;24(4):333-335.
Crossref Google Scholar
29

Vivarelli M, Massella L, Ruggiero B, et al. Minimal change disease. Clin J Am Soc Nephrol. 2017;12(2):332-345.
Crossref Google Scholar
30

Sever Sanja, Schiffer Mario. Actin dynamics at focal adhesions: a common endpoint and putative therapeutic target for proteinuric kidney diseases. Kidney Int. 2018;93(6):1298-1307.
Crossref Google Scholar
31

Ruotsalainen V, Ljungberg P, Wartiovaara J, et al. Nephrin is specifically located at the slit daphragm of glomerular podocytes. Proc Natl Acad Sci USA. 1999;96(14):7962-7967.
Crossref Google Scholar
32

Kawachi H, Fukusumi Y. New insight into podocyte slit diaphragm, a therapeutic target of proteinuria. Clin Exp Nephrol. 2020;24(3):193-204.
Crossref Google Scholar
33

Reidy K, Susztak K. Epithelial-mesenchymal transition and podocyte loss in diabetic kidney disease. Am J Kidney Dis. 2009;54(4):590-593.
Crossref Google Scholar
34

Henderson JM, Al-Waheeb S, Weins A, et al. Mice with altered alpha-actinin-4 expression have distinct morphologic patterns of glomerular disease. Kidney Int. 2008;73(6):741-750.
Crossref Google Scholar
35
KatamotoTOkadaKHirohashiYAutomated image analysis of a glomerular injury marker desmin in spontaneously diabetic Torii rats treated with losartanJ Endorinol201422114351

Katamoto T, Okada K, Hirohashi Y, et al. Automated image analysis of a glomerular injury marker desmin in spontaneously diabetic Torii rats treated with losartan. J Endorinol. 2014;221(1):43-51.

10.1530/JOE-14-0164
Crossref Google Scholar
36
LinDYLiSHouCYXuXGuoSZWangQQExploring the biological mechanism of qi deficiency syndrome with chronic obstructive pulmonary disease (COPD) based on integrated pharmacologyJ Tradit Chin Med Sci2021817281

Lin DY, Li S, Hou CY, Xu X, Guo SZ, Wang QQ. Exploring the biological mechanism of qi deficiency syndrome with chronic obstructive pulmonary disease (COPD) based on integrated pharmacology. J Tradit Chin Med Sci. 2021;8(1):72-81.

10.1016/j.jtcms.2021.01.003
Crossref Google Scholar
37
MaJYSunSXNiCProteomic analysis of overweight/obesity and related abnormal glucose and lipid metabolism caused by phlegm-dampness retentionJ Tradit Chin Med Sci202183224237

Ma JY, Sun SX, Ni C, et al. Proteomic analysis of overweight/obesity and related abnormal glucose and lipid metabolism caused by phlegm-dampness retention. J Tradit Chin Med Sci. 2021;8(3):224-237.

10.1016/j.jtcms.2021.07.008
Crossref Google Scholar
38
DingYJPanLPangBZhaoJXPathological analysis of diabetic nephropathy with micro-abdominal massJ New Chin Med2009112

Ding YJ, Pan L, Pang B, Zhao JX. Pathological analysis of diabetic nephropathy with micro-abdominal mass. J New Chin Med. 2009;1:1-2 [Chinese].
Google Scholar
39
XuJLiuHFMiaoGZEffects of qidi tangshen formulation in treating DKD patients with microalbuminuria and its effects on urine PCX and LAPJ Tianjin Univ Tradit Chin Med2020393280285

Xu J, Liu HF, Miao GZ, et al. Effects of qidi tangshen formulation in treating DKD patients with microalbuminuria and its effects on urine PCX and LAP. J Tianjin Univ Tradit Chin Med. 2020;39(3):280-285.
Google Scholar
40

Gao X, An ZC, He QY, Liu HF. Therapeutic effect of tianjingtongluo formula on renal tubular injury in diabetic nephropathy rats. Chin J Integr Tradit West Nephrol. 2018;19(2):109-112 [Chinese].
Google Scholar
Journal of Traditional Chinese Medical Sciences
Volume 9 Issue 1,
January 2022
Pages 69-77
DOI: 10.1016/j.jtcms.2022.01.003
Cite this article:
Yu B, Liu H, Gao X, et al. Effects of Qidi Tangshen granules and their separate prescriptions on podocytes in mice with diabetic nephropathy. Journal of Traditional Chinese Medical Sciences, 2022, 9(1): 69-77. https://doi.org/10.1016/j.jtcms.2022.01.003

518

Views

9

Downloads

0

Crossref

1

Scopus

Altmetrics
Received: 03 March 2021
Revised: 04 January 2022
Accepted: 04 January 2022
Published: 06 January 2022
© 2022 Beijing University of Chinese Medicine.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return